Potential of histone deacetylase inhibitors (HDACi) in the treatment of paediatric TEL/AML1–positive acute lymphoblastic leukaemia

1. Kornberg RD. Eukaryotic transcriptional control. Trends Cell Biol 1999; 9: M46–49.

2. Flaus A, Owen–Hughes T. Mechanisms for ATP–dependent chromatin remodelling. Curr Opin Genet Dev 2001; 11: 148–154.

3. Vignali M, Hassan AH, Neely KE, Workman JL. ATP–dependent chromatin–remodeling complexes. Mol Cell Biol 2000; 20: 1899–1910.

4. Fyodorov DV, Kadonaga JT. The many faces of chromatin remodeling: Switching beyond transcription. Cell 2001; 106: 523–525.

5. Lusser A, Kadonaga JT. Chromatin remodeling by ATP–dependent molecular machines. Bioassays 2003; 25: 1192–1200.

6. Strahl BD, Allis CD. The language of covalent histone modifications. Nature 2000; 403: 41–45.

7. Zhang Y, Reinberg D. Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes Dev 2001; 15: 2343–2360.

8. Berger SL. Histone modifications in transcriptional regulation. Curr Opin Genet Dev 2002; 12: 142–148.

9. Luo J, Nikolaev AY, Imai S, et al. Negative control of p53 by Sir2alpha promotes cell survival under stress Deacetylation of p53 modulates its effect on cell growth and apoptosis. Cell 2001; 107: 137–148.

10. Luo J, Su F, Chen D, Shiloh A, Gu W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 2000; 408: 377–381.

11. Gray SG, Ekstrom TJ. The human histone deacetylase family. Exp Cell Res 2001; 262: 75–83.

12. Guenther MG, Barak O, Lazar MA. The SMRT and N–CoR corepressors are activating cofactors for histone deacetylase 3. Mol Cell Biol 2001; 21: 6091–6101.

13. Zhang Y, Iratni R, Erdjument–Bromage H, Tempst P, Reinberg D. Histone deacetylases and SAP18, a novel polypeptide, are components of a human Sin3 complex. Cell 1997; 89: 357–364.

14. Dhordain P, Lin RJ, Quief S, et al. The LAZ3(BCL–6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression. Nucleic Acids Res 1998; 26: 4645–4651.

15. Hiebert SW, Lutterbach B, Amann J. Role of co–repressors in transcriptional repression mediated by the t(8;21), t(16;21), t(12;21), and inv(16) fusion proteins. Curr Opin Hematol 2001; 8: 197–200.

16. Melnick A, Licht JD. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999; 93: 3167–3215.

17. Melnick A, Licht JD. Histone deacetylases as therapeutic targets in hematologic malignancies. Curr Opin Hematol 2002; 9: 322–332.

18. Candido EP, Reeves R, Davie JR. Sodium butyrate inhibits histone deacetylation in cultured cells. Cell 1978; 14: 105–113.

19. Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 2003; 4: 13–18.

20. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001; 1: 194–202.

21. Grozinger CM, Chao ED, Blackwell HE, Moazed D, Schreiber SL. Identification of a class of small molecule inhibitors of the sirtuin family of NAD–dependent deacetylases by phenotypic screening. J Biol Chem 2001; 276: 38837–38843.

22. Su GH, Sohn TA, Ryu B, Kern SE. A novel histone deacetylase inhibitor identified by high–throughput transcriptional screening of a compound library. Cancer Res 2000; 60: 3137–3142.

23. Finnin MS, Donigian JR, Cohen A, et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999; 401: 188–193.

24. Gottlicher M, Minucci S, Zhu P, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. Embo J 2001; 20: 6969–6978.

25. Peart MJ, Smyth GK, van Laar RK, et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci U S A 2005; 102: 3697–3702.

26. Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2003; 2: 151–163.

27. Ungerstedt JS, Sowa Y, Xu WS, et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci U S A 2005; 102: 673–678.

28. Zelent A, Guidez F, Melnick A, Waxman S, Licht JD. Translocations of the RARalpha gene in acute promyelocytic leukemia. Oncogene 2001; 20: 7186–7203.

29. Warrell RP, Jr., Frankel SR, Miller WH, Jr., et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all–trans–retinoic acid). N Engl J Med 1991; 324: 1385–1393.

30. He LZ, Tolentino T, Grayson P, et al. Histone deacetylase inhibitors induce remission in transgenic models of therapy–resistant acute promyelocytic leukemia. J Clin Invest 2001; 108: 1321–1330.

31. Wang J, Hoshino T, Redner RL, Kajigaya S, Liu JM. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N–CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci U S A 1998; 95: 10860–10865.

32. Hiebert SW, Reed–Inderbitzin EF, Amann J, Irvin B, Durst K, Linggi B. The t(8;21) fusion protein contacts co–repressors and histone deacetylases to repress the transcription of the p14ARF tumor suppressor. Blood Cells Mol Dis 2003; 30: 177–183.

33. Rosato RR, Grant S. Histone deacetylase inhibitors in clinical development. Expert Opin Investig Drugs 2004; 13: 21–38.

34. Garcia–Manero G, Yang H, Bueso–Ramos C et al. Phase I study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2007; Oct 25 [Epub ahead of print].

35. Gojo I, Jiemjit A, Trepel JB, et al. Phase 1 and pharmacologic study of MS–275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 2007 Apr 1; 109(7): 2781–90.

36. Byrd JC, Marcucci G, Parthun MR, et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005 Feb 1; 105(3): 959–67. Epub 2004 Oct 5.

37. Children’s Oncology Group, Fouladi M, Furman WL, et al. Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children’s Oncology Group report. J Clin Oncol 2006 Aug 1; 24(22): 3678–85.

38. Raffoux E, Chaibi P, Dombret H, Degos L. Valproic acid and all–trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia. Haematologica. 2005 Jul; 90(7): 986–8.

39. Soriano AO, Yang H, Faderl S, et al. Safety and clinical activity of the combination of 5–azacytidine, valproic acid, and all–trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007 Oct 1;110(7):2302–8. Epub 2007 Jun 27.

40. Münster P, Marchion D, Bicaku E, et al. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol 2007 May 20; 25(15): 1979–85.

41. Tapan MK, Alessandra F, Farhad R, et al. A Phase I Study of the Combination of the Histone Deacetylase Inhibitor Vorinostat with Idarubicin in Advanced Acute Leukemia. 49th ASH meeting 2007.

42. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T–cell lymphoma. Oncologist 2007 Oct; 12(10): 1247–52.

43. Tsapis M, Lieb M, Manzo F, et al. HDAC inhibitors induce apoptosis in glucocorticoid–resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway. Int J Biochem Cell Biol. 2007; 39(7–8): 1500–9. Epub 2007 Mar 15.

44. Miller CP, Ban K, Dujka ME, et al. NPI–0052, a novel proteasome inhibitor, induces caspase–8 and ROS–dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood 2007 Jul 1;110(1): 267–77. Epub 2007 Mar 13.

45. Madzo J, Zuna J, Muzikova K, et al. Slower molecular response to treatment predicts poor outcome in patients with TEL/AML1 positive acute lymphoblastic leukemia: prospective real–time quantitative reverse transcriptase–polymerase chain reaction study. Cancer 2003 Jan 1; 97(1): 105–13.

46. Starkova J, Madzo J, Cario G, et al. The identification of (ETV6)/RUNX1–regulated genes in lymphopoiesis using histone deacetylase inhibitors in ETV6/RUNX1–positive lymphoid leukemic cells. Clin Cancer Res. 2007 Mar 15;13(6):1726–35. Epub 2007 Feb 26.

47. Zuna J, Ford AM, Peham M, et al. TEL deletion analysis supports a novel view of relapse in childhood acute lymphoblastic leukemia. Clin Cancer Res 2004 Aug 15; 10(16): 5355–60.

48. Hong D, Gupta R, Ancliff P, et al. Initiating and cancer–propagating cells in TEL–AML1–associated childhood leukemia. Science 2008 Jan 18; 319(5861): 336–9.